Default company panoramic image


OmniCyte is a pre-clinical biotech company addressing significant unmet needs in cancer.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Guilford, CT, US
  • Currency USD
  • Founded September 2016
  • Employees 2
  • Incorporation Type LLC

Company Summary

We are a pre-clinical biotech company and have developed a novel Immuno-Oncology platform technology that selectively activates the cancer immune system to target, infiltrate and destroy specific tumor types, without activating unrelated immune elements, which can cause immunotoxic side effects. Our technology can be engineered to safely attack numerous different tumor types. Our first two indications are ovarian cancer and small cell lung cancer


  • Default avatar
    Hans Christinger, MBA
    Default avatar
    Boris Shor, Ph.D.